Intest Res.  2017 Oct;15(4):475-486. 10.5217/ir.2017.15.4.475.

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies

• Hibi T
• Imai Y
• Murata Y
• Matsushima N
• Zheng R
• Gasink C

• KMID: 2396397
• DOI: http://doi.org/10.5217/ir.2017.15.4.475

Abstract

BACKGROUND/AIMS
Efficacy and safety of ustekinumab were evaluated in a Japanese subpopulation with moderately to severely active Crohn's disease (CD) in UNITI-1, UNITI-2 and IM-UNITI studies and results were compared with the overall population.
METHODS
Overall, patients in UNITI-1 (Japan, n=56; failed response to tumor necrosis factor antagonist) and UNITI-2 (Japan, n=26; failed response to prior conventional therapy) were randomized to placebo or ustekinumab intravenous induction (130 mg or ~6 mg/kg) at week 0. Responders to ustekinumab induction therapy (Japan, n=21) were randomized to placebo or ustekinumab (90 mg, subcutaneous) maintenance (every 12 weeks [q12w] or 8 weeks [q8w]) in IM-UNITI. The primary endpoint was clinical response at week 6 for induction studies and clinical remission at week 44 for maintenance study.
RESULTS
Percentage of patients achieving clinical response at week 6 was greater in ustekinumab 130 mg and ~6 mg/kg groups than in the placebo group (UNITI-1: 36.8% and 31.6% vs. 27.8%, respectively, for Japanese; 34.3% and 33.7% vs. 21.5%, respectively, for overall; UNITI-2: 37.5% and 55.6% vs. 11.1%, respectively, for Japanese; 51.7% and 55.5% vs. 28.7%, respectively, for overall). Clinical remission rate at week 44 during maintenance was greater in the ustekinumab 90 mg SC q12w and q8w groups than in the placebo group (50.0% and 55.6% vs. 25.0%, respectively, for Japanese; 48.8% and 53.1% vs. 35.9%, respectively, for overall). Efficacy and safety results observed in the Japanese subpopulation were generally consistent with those in the overall population.
CONCLUSIONS
Ustekinumab could be considered as a new therapeutic option for moderately to severely active CD in Japanese patients. Both ustekinumab induction and maintenance treatments were generally well tolerated (Clinical Trial Registration: NCT01369329, NCT01369342, NCT01369355).

Keyword

Crohn disease; Interleukin-12/23; Japan; Ustekinumab

MeSH Terms

Asian Continental Ancestry Group*
Crohn Disease*
Humans
Japan
Tumor Necrosis Factor-alpha
Ustekinumab*
Tumor Necrosis Factor-alpha
Ustekinumab

Figure

• 

  Fig. 1 Study design of phase 3 CD program for ustekinumab. Patients randomized to placebo and patients who were nonresponders to ustekinumab were eligible for nonrandomized maintenance dose after completion of induction study. aWeight range based ustekinumab doses approximating at 6 mg/kg; bIf there was no clinical response achieved at week 8, the study treatment was discontinued. TNF, tumor necrosis factor; IV, intravenous; q8w, every 8 weeks; q12w, every 12 weeks. Adapted from Feagan BG, et al. N Engl J Med 2016;375:1946-1960.19

• 

  Fig. 2 Primary endpoint in the overall study population and Japanese subpopulation. The primary efficacy outcome in induction and maintenance studies observed in Japanese subpopulation were similar to the global study population. aP<0.001 vs. placebo; bP<0.01 vs. placebo; cP=0.04. q8w, every 8 weeks; q12w, every 12 weeks.

• 

  Fig. 3 Median change in CDAI scores over time. In the induction studies and maintenance study, the median change in CDAI scores consistently improved with ustekinumab compared with that with placebo in the Japanese subpopulation and overall study population. All P<0.05 vs. placebo in the overall population of the UNITI-1, UNITI-2, and IM-UNITI studies. q12w, every 12 weeks; q8w, every 8 weeks. Panel B, D, and F are adapted from Feagan BG, et al. N Engl J Med 2016;375:1946-1960, with permission Massachusetts Medical Society.19

Reference

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066–2078. PMID: 19923578.

2. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126:1504–1517. PMID: 15168363.

3. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015; 12:205–217. PMID: 25732745.

4. Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol. 2009; 44:659–665. PMID: 19424654.

5. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016; 14:111–119. PMID: 27175111.

6. Hu PJ. Inflammatory bowel disease in Asia: the challenges and opportunities. Intest Res. 2015; 13:188–190. PMID: 26130991.

7. Ng SC, Tang W, Leong RW, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut. 2015; 64:1063–1071. PMID: 25217388.

8. Kanai T, Matsuoka K, Naganuma M, Hayashi A, Hisamatsu T. Diet, microbiota, and inflammatory bowel disease: lessons from Japanese foods. Korean J Intern Med. 2014; 29:409–415. PMID: 25045286.

9. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015; 8:66–82.

10. Tanida S, Ozeki K, Mizoshita T, et al. Managing refractory Crohn’s disease: challenges and solutions. Clin Exp Gastroenterol. 2015; 8:131–140. PMID: 25914555.

11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541–1549. PMID: 12047962.

12. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006; 130:323–333. PMID: 16472588.

13. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007; 132:52–65. PMID: 17241859.

14. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007; 357:228–238. PMID: 17634458.

15. Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011; 3:535–545. PMID: 22123062.

16. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371:1665–1674. PMID: 18486739.

17. Igarashi A, Kato T, Kato M, Song M, Nakagawa H;. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012; 39:242–252. PMID: 21955098.

18. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012; 367:1519–1528. PMID: 23075178.

19. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016; 375:1946–1960. PMID: 27959607.

20. Ministry of Health, Labour and Welfare. Basic principles on global clinical trials. Tokyo: Ministry of Health, Labour and Welfare;2007.

21. Ministry of Health, Labour and Welfare. Basic principles on global clinical trials (reference cases). Tokyo: Ministry of Health, Labour and Welfare;2012.

22. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015; 47:979–986. PMID: 26192919.

23. Inoue N, Tamura K, Kinouchi Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn’s disease. Gastroenterology. 2002; 123:86–91. PMID: 12105836.

24. Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014; 46:1017–1020. PMID: 25108385.

25. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013; 168:844–854. PMID: 23301632.

26. Gottlieb AB, Kalb RE, Langley RG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014; 13:1441–1448. PMID: 25607786.

27. Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res (Hoboken). 2015; 67:1739–1749. PMID: 26097039.